Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

CPYPP

  • Zoom
    CPYPP
  • CPYPP
Cat No: 17386
Biochemicals - More Biochemicals
Cayman

CPYPP is an inhibitor of the Rac activators dedicator of cytokinesis 2 (DOCK2; IC50 = 22.8 µM for DOCK2 guanine nucleotide exchange factor (GEF) activity), DOCK5, and DOCK180.{60263,60264} It is selective for these DOCK-A subfamily proteins over the D...

More

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Synonyms:
  • 4-[3-(2-chlorophenyl)-2-propen-1-ylidene]-1-phenyl-3,5-pyrazolidinedione
Correlated keywords:
  • 1413941-71-5 1413941-83-9 1426543-36-3 DOCK-2 5 9 180 DOCKA DOCKD Lipopolysaccharide
Product Overview:
CPYPP is an inhibitor of the Rac activators dedicator of cytokinesis 2 (DOCK2; IC50 = 22.8 µM for DOCK2 guanine nucleotide exchange factor (GEF) activity), DOCK5, and DOCK180.{60263,60264} It is selective for these DOCK-A subfamily proteins over the DOCK-D subfamily member DOCK9.{60263} CPYPP (100 µM) prevents chemokine-induced Rac activation in T and B cells. It also inhibits chemokine-induced migration of T and B cells. CPYPP (5 mg/animal, i.p.) reduces migration of T cells to peripheral lymph nodes in mice following adoptive transfer of spleen cells from knock-in mice expressing GFP-tagged DOCK2. It also reduces myeloperoxidase (MPO) activity in lung tissue, LPS-induced cytokine release in serum, and the severity of lung injury in a mouse model of endotoxemia-induced acute lung injury when administered at a dose of 250 mg/kg.{60265}
Size 5 mg
Shipping dry ice
CAS Number 310460-39-0
Molecular Formula C18H13ClN2O2
SMILES O=C(N(C1=CC=CC=C1)NC/2=O)C2=C/C=C/C3=C(Cl)C=CC=C3
Molecular Weight 324,8
Formulation A crystalline solid
Purity ≥98% (mixture of isomers)
Custom Code 2930.90
UNSPSC code 12352100

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

Search